Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.
about
Tumor stroma as targets for cancer therapyThe integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cellsAngiomodulin, a marker of cancer vasculature, is upregulated by vascular endothelial growth factor and increases vascular permeability as a ligand of integrin αvβ3Angiogenesis, lymphangiogenesis, and melanoma metastasis.Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.siRNA-mediated silencing of integrin β3 expression inhibits the metastatic potential of B16 melanoma cells.Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesSynstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects.Enhanced trophic factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-Lysine (GHK)-modified alginate hydrogelsTargeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.αv-Integrin isoform expression in primary human tumors and brain metastases.A fluorescent Arg-Gly-Asp (RGD) peptide-naphthalenediimide (NDI) conjugate for imaging integrin α(v)β(3) in vitro.Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.Active Sequences Collection (ASC) database: a new tool to assign functions to protein sequences.AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer.Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer PatientsInhibitory Effects of PEI-RGD/125I-(αv) ASODN on Growth and Invasion of HepG2 Cells.Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties.Cyclic arginine-glycine-aspartic acid peptide inhibits macrophage infiltration of the kidney and carotid artery lesions in apo-E-deficient mice.Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation.Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma MultiformeComputational modeling of synergistic interaction between αVβ3 integrin and VEGFR2 in endothelial cells: Implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides
P2860
Q27015980-03256A03-9710-4D47-A513-88781750AFD1Q28474747-BDA541B2-C68B-4BD0-9C86-F08A38F2C87EQ33913526-41A386AA-624D-4A82-BFCC-122C384BD51EQ35146591-C9073C8D-A74C-4620-8FE3-2AFA29B3C786Q35701298-E2E37B26-975E-49E4-A4C6-87AE26B10C3AQ36642289-2290801F-007C-4668-A8B0-72DD409BF67DQ36807993-73149444-2DBB-4BF9-897C-E564139EA572Q36836804-1E57BA68-EDE4-4F40-8886-9BCCCAAB317AQ37234281-25EB0B05-A438-4B9F-996E-58B3BA5980D2Q37410430-AAF980BB-3576-4BA8-8B5E-BA35D23B3FBDQ37686574-154A760F-30CB-4FB8-AC66-8803CFC4192FQ37688207-A31167B0-3747-47AE-BB74-87FC6FECA4A8Q37815128-6A8AF5DA-E808-4444-9B55-2631634FAE65Q38161395-DFDDA602-73F0-46F6-BF6B-7D46D291EF73Q38396834-281DD02E-B605-40AC-8595-1A88016DA8D7Q38913470-4E780DF6-5F4B-4140-9C9D-4916B27C963FQ39677540-3AC53BDC-7CA0-476E-97B4-A67806331516Q39727083-7F4AC0F1-6420-426E-86FB-3A6670442301Q39790308-0AC11FBB-32D3-4C3F-AA49-532AB94F1246Q40443936-8FED67B0-81EE-4858-B6E2-41C0D330CFADQ41434182-948D3430-149C-43AA-A420-849DE5B24271Q41670908-BD2AEE54-5AB4-4C11-A3E2-4A13C10B3E69Q42532649-53826C9F-299C-4D38-B289-5DEE64269D1EQ44445174-5957F7FE-921B-4FB2-AB02-204C4D892902Q46655131-6DEAF4AE-47E1-4FFD-BB26-8B0D8F1F1BAEQ52668185-AD85BF12-D379-42F0-9282-763B6FD4CAEAQ57141680-D0B74F6C-626B-4E2B-8D3D-7700D34FF726Q57467572-255DAA6A-8F65-43DE-9069-B79CC7436383
P2860
Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Inhibition of the alpha-nu int ...... asis of solid tumours in vivo.
@en
type
label
Inhibition of the alpha-nu int ...... asis of solid tumours in vivo.
@en
prefLabel
Inhibition of the alpha-nu int ...... asis of solid tumours in vivo.
@en
P2093
P2860
P356
P1476
Inhibition of the alpha-nu int ...... asis of solid tumours in vivo.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600141
P407
P577
2002-03-01T00:00:00Z
P5875
P6179
1027139783